Related Experiment Video
Updated: Jun 22, 2026

Production and Testing of Antimicrobial Peptides and Their Mimics
Published on: April 10, 2026
Antimicrobial and host defense peptides for therapeutic use against multidrug-resistant pathogens: new hope on the
Bettina Bommarius1, Daniel Kalman
1Emory University, Department of Pathology and Laboratory Medicine, Atlanta, GA 30322, USA. bbommar@emory.edu
Abstract:
The concept of using antimicrobial peptides (AMPs) and host defense peptides (HDPs) as therapeutics was first introduced in the late 1990s. However, an AMP drug has yet to reach the market. AMPs and HDPs have intriguing potential as therapeutics: the peptides are evolutionary conserved, and are critical components of the innate immune system of all eukaryotes; their evolution pre-dates the appearance of the adaptive immune system; and they do not readily engender bacterial resistance. Nevertheless, there are significant obstacles to the use of AMPs and HDPs in humans, including the need to conduct clinical trials to demonstrate efficacy, and the capacity to manufacture AMPs and HDPs in a cost-effective manner. Progress in both of these areas would support the exciting possibility that AMPs and HDPs could be developed as therapeutics that kill pathogens and facilitate the immune response.
More Related Videos
Related Concept Videos
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Clinical Significance of Antibiotic Resistance
Microbiota Modulation by Antibiotics
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Microorganisms in Medicine and Therapeutics
Gene Regulation in Microbial Communities: Quorum Sensing

